Pregled bibliografske jedinice broj: 1261384
The DNA methylation of LGALS3 gene as a prostate cancer biomarker
The DNA methylation of LGALS3 gene as a prostate cancer biomarker // FEBS Open Bio, 12 (2022), Suppl 1
Lisabon, Portugal, 2022. str. 86-87 doi:10.1002/2211-5463.13440 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1261384 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The DNA methylation of LGALS3 gene as a prostate
cancer biomarker
Autori
Abramović, Irena ; Pezelj, Ivan ; Kuliš, Tomislav ; Ulamec, Monika ; Bulimbašić, Stela ; Katušić Bojanac, Ana ; Sinčić, Nino
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
FEBS Open Bio, 12 (2022), Suppl 1
/ - , 2022, 86-87
Skup
The Biochemistry Global Summit, 25th IUBMB Congress, 46th FEBS Congress, 15th PABMB Congres
Mjesto i datum
Lisabon, Portugal, 09.07.2022. - 14.07.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
prostate cancer ; LGALS3 ; liquid biopsy ; biomarkers
Sažetak
The unmet challenge for clinicians in prostate cancer (PCa) management represents its differentiation from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research is directed towards cfDNA from liquid biopsies as potential PCa biomarkers, especially DNA methylation since it plays an important role in prostate cancer development. In the present work, CpG methylation of the LGALS3 gene in cfDNA isolated from blood and seminal plasma of PCa and BPH patients was investigated using pyrosequencing ; as well as DNA methylation of LGALS3 in tumor tissue, surrounding non-tumor tissue, and BPH tissue. Liquid biopsy samples were taken from patients with elevated PSA levels before prostate biopsy, who were subsequently divided into two groups (42 with PCa and 55 with BPH) according to the histopathology report. Statistically significant higher cfDNA methylation in seminal plasma of BPH patients was found compared to cancer ones. Still, in both groups, low methylation frequency was found ; median in BPH patients was 4 %, while in PCa patients 3 %. In tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding non-tumor tissue and BPH tissue. However, cfDNA from blood plasma did not reflect that change. In conclusion, DNA hypermethylation of the LGALS3 gene represents an event specific for prostate cancer compared to surrounding non-tumor tissue and BPH tissue, but it does not reflect itself on cfDNA in blood and seminal plasma as liquid biopsy samples. Therefore, cfDNA methylation of LGALS3 in blood and seminal plasma did not meet the supposed potential for differentiation between PCa and BPH ; but DNA methylation of LGALS3 in tissue could be used as a biomarker for PCa.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
--UIP-2017-05-8138 - Epigenetički biomarkeri raka prostate (epiPro) (Sinčić, Nino) ( CroRIS)
--KK.01.1.1.01.0008 - Znanstveni centar izvrsnosti za reproduktivnu i regenerativnu medicinu – istraživanja novih platormi i potencijala (CERRM) (Ježek, Davor; Vukičević, Slobodan) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb
Profili:
Nino Sinčić
(autor)
Irena Abramović
(autor)
Ana Katušić Bojanac
(autor)
Tomislav Kuliš
(autor)
STELA BULIMBAŠIĆ
(autor)
Monika Ulamec
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE